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Abstract
Background: Many viruses recognize specific sugar residues, particularly sulfated or sialylated
glycans, as the infection receptors. A change of sialic acid (2-6)-linked galactose (SA-α2,6Gal) to
SA-α2,3Gal determines the receptor for avian flu infection. The receptor for enterovirus 71 (EV71)
infection that frequently causes fatal encephalitis in Asian children remains unclear. Currently, there
is no effective vaccine or anti-virus agent for EV71 infection. Using DLD-1 intestinal cells, this study
investigated whether SA-linked glycan on DLD-1 intestinal cells was a receptor for EV71, and
whether natural SA-linked sugars from human milk could block EV71 infection.
Results: EV71 specifically infected DLD-1 intestinal cells but not K562 myeloid cells. Depletion of
O-linked glycans or glycolipids, but not N-linked glycans, significantly decreased EV71 infection of
DLD-1 cells. Pretreatment of DLD-1 cells with sialidase (10 mU, 2 hours) significantly reduced 20-
fold EV71 replication (p < 0.01). Taken together, these results suggest that SA-linked O-glycans and
glycolipids, but not N-glycans, on DLD-1 cells were responsible for EV71 infection. Purified SA-
α2,3Gal and SA-α2,6Gal from human milk significantly inhibited EV71 infection of DLD-1 cells,
indicating terminal SA-linked glycans could be receptors and inhibitors of EV71 infection.
Conclusion: This is the first in the literature to demonstrate that EV71 uses SA-linked glycans as
receptors for infection, and natural SA-linked glycans from human milk can protect intestinal cells
from EV71 infection. Further studies will test how a SA-containing glycan can prevent EV71 in the
future.
Introduction
Many viruses recognize specific sugar residues, particu-
larly sulfated or sialylated glycans, as the infection recep-
tors. Avian influenza virus and human influenza virus use
different sugar residues as their receptors, resulting in dif-
ferent host range of infections [1]. Enterovirus 71 (EV71)
which prevails almost every summer season and causes
hand-foot-mouth disease is frequently complicated with
fatal encephalitis in Asia, and even Europe [2-6]. Cur-
rently, there is neither vaccine available for prevention of
EV71, nor antiviral treatment for EV71 infection. Before
development of effective antiviral agents or specific vac-
cine available to control epidemics of EV71, identification
of the receptor(s) for EV71 and block of the receptor(s)
may be a good regimen for prevention of EV71 infection.
Sialic acid (SA) also known as neuraminic acid is usually
linked to galactose or other sugar residues as an antenna
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of blood group antigens, tumor antigens or viral receptors
[7]. Gastrointestinal and respiratory epithelial cells
expressed abundant SA-containing glycoproteins and SA-
containing glycolipids [1,8,9]. It is known that sialic acid-
α2,6 galactose (SA-α2,6Gal) epitope is a receptor for
human influenza virus [1] and sialic acid-α2,3galactose
(SA-α2,3Gal) is a receptor for coxackievirus A24 [8]. The
transmission route of the EV71 is fecal-oral and/or drop-
let-aerosol route, and the receptor for EV71 is unknown
[3]. We, therefore, postulated that EV71 might use the SA-
linked glycan on intestinal epithelial cells as a receptor,
and natural SA-linked glycans may prevent human intes-
tinal cells from EV71 infection.
This study was conducted to investigate whether deple-
tion of glycolipids, N-linked glycans or O-linked glycans
on DLD-1 intestinal cells could avoid EV71 infection, and
administration of SA-linked sugars from human milk
could block EV71 infections. If natural SA-linked sugars
could block EV71 infection, SA-linked glycans may be
made to prevent EV71 infections.
Results and Discussion
EV71 infection of DLD-1 intestinal cells
Experiments were initially performed to study whether
EV71 could specifically infect DLD-1 intestinal cells.
Using multiplication of index (MOI) of 10, it was found
that EV71 could infect and replicate in DLD-1 cells in 4
hours, and caused a dramatic increase of replication in 24
hours of EV71 infection. As determined by RT-PCR analy-
sis of the virus titers, the virus replication (RNA copies of
EV71) increased from 67 copies of EV71 per ml in one
hour to more than 106 copies/ml in 2 days (Figure 1A). As
demonstrated by indirect immunofluorescent assay (IFA),
EV71 replication was detectable in 24 hours of infection
(Figure 1B). In contrast, EV71 did not infect K562 mye-
loid cells in 24 hours (Figure 1C). This result suggests that
EV71 infection has tissue specificity. No detectable infec-
tion of EV71 on K562 myeloid cells by IFA might be due
to lack of EV71 receptors on myeloid cells or limited rep-
lication of EV71 in K562 myeloid cells.
SA-linked O-glycan and glycolipid but not N-glycan 
responsible for EV71 infection
To determine whether glycans were involved in the EV71
infection of intestinal cells, we tested whether depletion
of N-glycans, O-glycans or glycolipids blocked EV71 infec-
tion of DLD-1 cells. We used benzyl N-acetyl-α-D-galac-
tosaminide (3 mM), tunicamycin (0.2 mg/ml) and
phosphotidylinositol-specific phospholipase (5 U/ml) to
deplete O-linked glycans, N-linked glycans and glycolip-
ids of DLD-1 cells, respectively. It was found that deple-
tion of O-linked glycan or glycolipid, but not N-linked
glycan, significantly decreased EV71 infection of DLD-1
cells (Figure 2). Particularly, O-linked glycan was the
major entry of EV71 infection because depletion of O-gly-
cans by benzyl N-acetyl-α-D-galactosaminide (3 mM)
reduced the most EV71 infection (P = 0.006). This is com-
patible to a recent report demonstrating a sialomucin (O-
linked glycoprotein) membrane protein (CD162) as a
functional receptor for enterovirus 71 infection [10].
Infection of DLD-1 cells by EV71 Figure 1
Infection of DLD-1 cells by EV71. EV71 infected and rep-
licated in DLD-1 cells within 4 hours (4 H), and rapidly repli-
cated in 24 hours (24 H) (A). The replication of EV71 in 
DLD-1 cells could be visible by specific antibody directed 
immunofluorescent staining (B). In contrast, EV71 did not 
infect K562 myeloid cells in 24 hours (C). Data presented are 
calculated from 4 experiments.
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O-glycans and glycolipids but not N-glycans responsible for  the EV71 infection Figure 2
O-glycans and glycolipids but not N-glycans responsi-
ble for the EV71 infection. O-glycan synthesis inhibitor, 
benzyl N-acetyl-α-D-galactosaminide and glycolipid anchor-
age inhibitor, phosphotidylinositol-specific phospholipase, but 
not N-glycan synthesis inhibitor, tunicamycin, significantly 
inhibited EV71 infections. Data presented were calculated 
from three experiments.
0
20
40
60
80
100
EV 71 EV 71+Benzyl-a-GalNAc EV 71+Tunicamycin EV 71+phospholipase C
E
V
 
7
1
 
i
n
f
e
c
t
i
o
n
 
(
%
)
EV 71
Benzyl-D-GalNAc
Tunicamycin
Phospholipase C
+                     +                      +                   +                  
– +                      – –
– – +                       –
–– – +
p =0.04
p =0.75
p =0.006Virology Journal 2009, 6:141 http://www.virologyj.com/content/6/1/141
Page 3 of 6
(page number not for citation purposes)
Inhibition of EV71 infection in DLD-1 cells by sialidase 
treatment
Considering O-linked glycans and glycolipids usually
have a variety of terminal sialic acid (SA) residues that
may contribute to the binding of EV71, we depleted sur-
face SA from SA-α2,3 Gal and SA-α2,6Gal of DLD-1 cells
by preincubation of the α2,3 and α2,6 sialidase. The sial-
idase treatment at 2, 10, and 50 mU/ml for 2 hours signif-
icantly decreased EV71-infected cells of DLD-1 cells in
immunoflueorescent staining (Figure 3, upper panel).
Pretreatment of sialidase also significantly reduced the
EV71 replication in DLD-1 cells for 3 days from 1.7 × 106
copies/ml down to 7.0 × 104 copies/ml, with more than
20-fold reduction (Figure 3, lower panel). This experi-
ment suggests that SA-linked glycans on intestinal cells are
responsible for the entry of EV71 infection. Pretreatment
of sialidase directed against SA-α2,3Gal and SA-α2,6Gal
significantly (P < 0.01) reduced EV71 infection suggesting
sialylated galactose epitopes are responsible for EV71
infection of DLD-1 intestinal cells. Experiments were next
performed to study whether natural SA-containing sugars
such as SA-α2,3Gal and SA-α2,6Gal could block EV71
infection in DLD-1 intestinal cells below.
Blockade of EV71 infection by SA-derived glycans from 
milk
Purified SA-α2,3Gal (molecular weight 633) and SA-
α2,6Gal (molecular weight 655) from human milk (0.25
mg/ml) were used to inhibit EV71 infection of DLD-1
cells. As showed in Figure 4, incubation of SA-α2,3Gal
and SA-α2,6Gal with EV71 before infection significantly
(P = 0.034) inhibited EV71 infection of DLD-1 intestinal
cells. Both SA-α2,3Gal and SA-α2,6Gal from human milk
could inhibit EV71 infections, suggesting human breast
feeding might prevent infants from EV71 infection via gas-
trointestinal tract.
Materials and methods
Study design. This study initially studied whether EV71
specifically infected DLD-1 intestinal cells, but not K562
myeloid cells. Using DLD-1 intestinal cells which possess
abundant sialylated glycans on cell surface, we tested
whether depletion of glycolipids or glycoproteins (N-
linked glycoprotein or O-linked glycoproteins) blocked
EV71 infection, and sialidase depletion of SA residues on
DLD-1 cells protected DLD-1 cells from EV71 infection,
indicating SA-linked glycan responsible for the entry of
EV71 infection. Finally, we used SA-linked glycans puri-
fied from human milk to block EV71 infection of DLD-1
cells in order to validate SA-linked galactose residues
responsible for EV71 infection.
Preparation of EV71. A clinical isolate of EV71 defined by
EV71-specific antibody was obtained from the Laboratory
of Virology, Department of Pathology, Chang Gung
Memorial Hospital, Kaohsiung. EV71 were cultured and
Sialidase treatment of DLD-1 cells decreased EV71 infection Figure 3
Sialidase treatment of DLD-1 cells decreased EV71 infection. DLD-1 cells pre-treated with different doses of sialidase 
for 2 hours significantly reduced EV71 infection in 24 hours under immunofluorescent assay (upper panel). The treatment of 
sialidase at 10 mU/ml (P < 0.01) or at 50 mU/ml (P < 0.001) significantly inhibited EV71 infection of DLD-1 cells for 3 days as 
analyzed by qRT-PCR analysis of EV71 titers (lower panel). Data presented are derived from 4 experiments.
ıįņĬıı
ĶįņĬıĶ
ĲįņĬıķ
ĳįņĬıķ
ĳįņĬıķ
ĴįņĬıķ
EV 71 EV 71+sialidase
2mU/ml
EV 71+sialidase
10mU/ml
EV 71+sialidase
50mU/ml
E
V
 
7
1
 
c
o
p
i
e
s
 
(
 
x
 
1
0
4
)
250
200
150
100
50
0
EV71 EV71 + sialidase
2 mU/ml
EV71 + sialidase
10 mU/ml
EV71 + sialidase
50 mU/ml
P<0.01
P<0.001Virology Journal 2009, 6:141 http://www.virologyj.com/content/6/1/141
Page 4 of 6
(page number not for citation purposes)
harvested from Vero cells. Vero cells at 5 × 105 cells/ml
were cultured in 75 cm2 culture flasks for over night, and
inoculated with EV71 at multiplicity of infection (MOI) =
2 for 6 days. When more than 60% Vero cells revealed
cytopathic effect (CPE), the total cell pellet was set to
freeze and thaw for 3 times before the virus harvested by
centrifugation at 1500 g for 10 minutes to separate viruses
from cell debris. The virus titer was adjusted to 2 × 107
copies/ml based on RT-PCR quantification of EV71 virus
copies (Figure 5), and stored in aliquots at -80°C before
studies.
Culture of human intestine epithelial cell line. We used
DLD-1 intestinal epithelial cells as a target of EV71 infec-
tion, and K562 myeloid leukemia cells were used as con-
trol cells for comparison. The DLD-1 and K562 cell lines
were obtained from Food Industrial Research Institute,
Hsin-chu, Taiwan. The reason to use intestinal cell line is
because it can express different levels of SA-linked glycans
resembling neonatal rat intestine [9]. DLD-1 cells were
cultured in Roswell Park Memorial Institute 1640
(RPMI1640) medium with 10% fetal bovine serum, and
harvested into 2 × 106 cells/ml for testing whether deple-
tion of SA-linked glycans on DLD-1 cells by sialidase treat-
ment reduced EV71 infection. Experiments were also
performed to differentiate whether different natural SA-
linked glycans such as SA-α2,3Gal or SA-α2,6Gal could
protect against EV71 infections.
Determination of EV71 infection by indirect immunoflu-
orescence and RT-PCR analysis. Infection of EV71 was
assessed by an indirect immunofluorescent staining with
an EV71-specific monoclonal antibody (Chemicon Inc.
CA). DLD-1 cells (2 × 105 cells/ml) with and without sial-
idase pre-treatment for 2 hours were subjected to EV71
infection. The EV71 infected DLD-1 cells were harvested
in one day for staining with mouse anti-EV71 monoclonal
antibody or nonspecific antibody after cold acetone fixa-
tion, followed by FITC-labeled goat anti-mouse immu-
noglobulin antibody for fluorescent visualization. Cells
were also harvested in 3 days for quantification of EV71
replication by a real time quantitative RT-PCR (qRT-PCR)
analysis as previously described [11]. The primers used to
detect EV71 RNA copies by SYBR Green fluorescent RT-
PCR were forward: 5'-CCCCTGAATGCGGCTAATC-3' and
reverse: 5'-CCATATAGCTATTGGATTGGCCA-3'. The cop-
ies of virus titers were calculated based on a standard curve
made by a series of well-known RNA copies of EV71.
Differentiation of the SA-containing glycoproteins and
glycolipids responsible for EV71 infection. Sugar residues
on cell surface are usually linked to protein, called glyco-
protein, or linked to lipid, called glycolipid. Employing
inhibitors of protein glycosylation and lipid glycosylation
synthesis, we investigated if the SA-based residue respon-
sible for EV71 infection stems from glycoprotein or gly-
colipid. To test whether N-linked or O-linked
sialylglycoprotein on DLD-1 cells was the receptor for
EV71, DLD-1 cells (1 × 106 cells/ml) were respectively
incubated with 3 mM benzyl N-acetyl-α-D-galactosamin-
ide (Sigma-Aldrich Inc., St. Louis, MO) for 48 hours or
with 0.2 mg/ml tunicamycin (Sigma-Aldrich Inc.) for 24
hours before subjected to EV71 binding assay at MOI =
10. To test whether sialylglycolipid on DLD-1 cells was the
receptor for EV71, DLD-1 cells (1 × 106 cells/50 μl) were
incubated with 50 μl phosphotidylinositol-specific phos-
pholipase (5 U/ml) purchased from Sigma-Aldrich Inc.
for 90 minutes before subjected to the test of EV71 bind-
ing assay. The EV71 binding assay was performed within
one hour after washing out the treatment of specific inhib-
itor because DLD-1 cells in the inhibitor-free condition
could re-express glycoprotein or glycolipid that might
interfere the experimental interpretation.
Sources of sialidase and natural SA-linked glycans: The
sialidase (α2-3, 6-sialidase, Clostridium perfringens) that
can cleave SA from SA-α2,3Gal and/or SA-α2,6Gal com-
pounds was purchased from Calbiochem Inc., Darmstadt,
Germany. For experiments, DLD-1 cells were pretreated
with 2, 10 or 50 mU/ml sialidase for 2 hours before sub-
jected to EV71 infections for 24 hours at MOI = 10.
Human milk SA-α2,3Gal (97% purity) and SA-α2,6Gal
(98% purity) were purchased from Sigma-Aldrich Inc. (St.
Louis, MO) and tested for inhibition of EV71 infections.
Determination of SA-linked sugar residue as a receptor
and inhibitor of EV 71 infection by qRT-PCR. To validate
whether SA-linked sugar residues were receptors for EV71
Inhibition of EV71 infection in DLD-1 cells by SA-α2,3Gal  and SA-α2,6Gal Figure 4
Inhibition of EV71 infection in DLD-1 cells by SA-
α2,3Gal and SA-α2,6Gal. DLD-1 cells co-incubated with 
SA-linked galactose (SA-α2,3Gal or SA-α2,6Gal) significantly 
(P = 0.034) reduced the EV71 infection for 3 days as quanti-
fied by RT-PCR analysis. Data presented are calculated from 
4 experiments.
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infection, EV71 (2 × 106 copies/ml) were co-incubated
with SA-α2,3Gal (0.25 mg/ml) or SA-α2,6Gal (0.25 mg/
ml) 15 minutes before added to infect DLD-1 cells (2 ×
105 cells/ml) for 3 days. Replication of EV71 in DLD-1
cells was determined by qRT-PCR detection as described
above.
Data management and statistics. Specific infection of
EV71 to DLD-1 cells was compared to the control cell line,
K562, myeloid leukemia cells. Binding of EV71 to SA-
linked sugars was validated by depletion of SA by sialidase
treatment. Inhibition of EV71 by different SA-linked sugar
residues was analyzed by non-parametric analysis of
Mann-Whitney U test. Chemical structures of the SA-
linked compounds were drawn by the software of
Chemwindow 6.0 (Bio-Rad Inc., Hercules, CA).
Conclusion
This is the first in the literature to demonstrate that both
SA-α2,6Gal and SA-α2,3Gal are responsible for EV71
infection of DLD-1 intestinal cells. Interruption of sugar-
lectin interactions for antiviral treatment has been
recently described [12]. Natural SA-containing glycans in
human milk could inhibit EV71 infections, suggesting
that human breast feeding may prevent infants from EV71
infection. Based on a strategy to link a SA-derived sugar
residue which can compete EV71 invasion receptor to an
Culture and quantification of EV71 Figure 5
Culture and quantification of EV71. EV71 were cultured in Vero cells at MOI = 2 until visible cytopathic effect (CPE) (A), 
and subjected to qRT-PCR analysis of virus titer (B). Based on qRT-PCR detection of a series of well-known EV71 titers (C), 
the virus titers were determined by an interpolation on the standard curve (D).
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A proposed SA-based "double-edge sword" on blocking and  destructioing of EV71 infections Figure 6
A proposed SA-based "double-edge sword" on block-
ing and destructioing of EV71 infections. SA (α2,6)-
linked galactose can block EV71 infection by competition of 
sugar receptor, and the galactose can be linked with cationic 
compounds such as lactoferrin or chitosan for destruction of 
EV71.
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antiviral agent such as cationic protein, lactoferrin, which
can direct against EV71 by targeting viral envelope [13], or
other cationic compounds such as chitosan that possesses
not only cationic charge but also feasibility of making
nanoparticles, we may be able to use the SA-linked antivi-
ral agent as a "double-edge sword" to bind EV71 and
destruct EV71 simultaneously, as shown in Figure 6. Inter-
pretation of this in vitro study is limited by the lack of
infectivity data and lack of data from animal model to
support the infection inhibition by IFA and PCR assays.
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